

Cezar A Iliescu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6614889/publications.pdf>

Version: 2024-02-01

118
papers

2,658
citations

218381

26
h-index

214527

47
g-index

121
all docs

121
docs citations

121
times ranked

2773
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 202-212.	0.8	34
2	Acute coronary syndrome in patients with cancer. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 275-290.	0.6	4
3	Predictors of Recurrence and Survival in Cancer Patients With Pericardial Effusion Requiring Pericardiocentesis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	3
4	Myocardial Dysfunction in Patients with Cancer. <i>Heart Failure Clinics</i> , 2022, 18, 361-374.	1.0	1
5	Reclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease. <i>Medicina (Lithuania)</i> , 2022, 58, 884.	0.8	1
6	Transcatheter and surgical aortic valve replacement impact on outcomes and cancer treatment schedule. <i>International Journal of Cardiology</i> , 2021, 326, 62-70.	0.8	6
7	Effectiveness and safety of same day discharge after left atrial appendage closure under moderate conscious sedation. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 912-916.	0.7	14
8	Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management. <i>Korean Circulation Journal</i> , 2021, 51, 579.	0.7	3
9	QT Prolongation in Cancer Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 613625.	1.1	10
10	Structural Transcatheter Cardiac Interventions in the Cardio-Oncology Population. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	2
11	Rate of Progression of Aortic Stenosis in Patients With Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 644264.	1.1	2
12	Radiation-Induced Vascular Disease—A State-of-the-Art Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 652761.	1.1	28
13	How to Diagnose and Manage QT Prolongation in Cancer Patients. <i>JACC: CardioOncology</i> , 2021, 3, 145-149.	1.7	14
14	Prognostic Factors and Overall Survival After Pericardiocentesis in Patients With Cancer and Thrombocytopenia. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 638943.	1.1	2
15	Machine Learning-Augmented Propensity Score Analysis of Percutaneous Coronary Intervention in Over 30 Million Cancer and Non-cancer Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 620857.	1.1	20
16	Percutaneous Muscular Ventricular Septal Defect Closure with 2D Transthoracic Echocardiography: Can We Sufficiently Visualize It?. <i>Eurasian Journal of Medicine</i> , 2021, 53, 144-147.	0.2	0
17	Single-access dual-injection technique (SADIT) for high-risk PCI with Impella CP. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1138-1140.	0.7	2
18	Coronary Stent Healing in Cancer Patients—An Optical Coherence Tomography Perspective. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 665303.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Cardiac Magnetic Resonance Predicting Outcomes Among Patients at Risk for Cardiac AL Amyloidosis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 626414.	1.1	8
20	Manual Aspiration Thrombectomy for Embolic Acute Mesenteric Ischemia. <i>Texas Heart Institute Journal</i> , 2021, 48, .	0.1	0
21	Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 1725-1735.	2.9	51
22	TAVR and cancer: machine learning-augmented propensity score mortality and cost analysis in over 30 million patients. <i>Cardio-Oncology</i> , 2021, 7, 25.	0.8	7
23	Los confinamientos de la población por el Covid-19 pueden empeorar las desigualdades socioeconómicas que impactan de forma desproporcionada en las minorías raciales: rentabilidad aumentada por aprendizaje automático y análisis ético computacional. <i>Medicina Y Etica: Revista Internacional De Bioetica, Deontologia Y Etica Medica</i> , 2021, 32, 759-800.	0.1	0
24	TAVR in Cancer Patients: Comprehensive Review, Meta-Analysis, and Meta-Regression. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 641268.	1.1	8
25	How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia. <i>JACC: CardioOncology</i> , 2021, 3, 452-456.	1.7	5
26	Interventional Strategies in Cancer-induced Cardiovascular Disease. <i>Current Oncology Reports</i> , 2021, 23, 133.	1.8	2
27	Clinical Impact of Cardiovascular Magnetic Resonance in Cancer Patients With Suspected Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 734820.	1.1	2
28	Stress cardiomyopathy in hospitalized patients with cancer: machine learning analysis by primary malignancy type. <i>ESC Heart Failure</i> , 2021, , .	1.4	9
29	The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 258.	0.5	3
30	Cancer treatment resumption in patients with new-generation drug-eluting stents. <i>Coronary Artery Disease</i> , 2021, 32, 295-301.	0.3	8
31	Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 377-387.	0.8	2
32	Percutaneous Coronary Intervention in Patients With Gynecological Cancer: Machine Learning-Augmented Propensity Score Mortality and Cost Analysis for 383,760 Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 793877.	1.1	2
33	Halloween in the Cath Lab: spider web pericardial effusion. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 317.	0.5	0
34	Assessment of Vascular Patency and Inflammation with Intravascular Optical Coherence Tomography in Patients with Superficial Femoral Artery Disease Treated with Zilver PTX Stents. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 101-107.	0.3	1
35	Percutaneous coronary intervention and in-hospital outcomes in patients with leukemia: a nationwide analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 53-63.	0.7	20
36	Opportunities for improved cardiovascular disease prevention in oncology patients. <i>Current Opinion in Cardiology</i> , 2020, 35, 531-537.	0.8	6

#	ARTICLE	IF	CITATIONS
37	The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103006.	2.0	14
38	Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunotherapy. <i>JACC: Case Reports</i> , 2020, 2, 2095-2100.	0.3	6
39	State-of-the-art Review: Interventional Onco-Cardiology. Current Treatment Options in <i>Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	3
40	Identifying Hemostatic Thresholds in Cancer Patients Undergoing Coronary Angiography Based on Platelet Count and Thromboelastography. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 9.	1.1	9
41	Impact of Cardiopulmonary Resuscitation on Survival in Cancer Patients. <i>JACC: CardioOncology</i> , 2020, 2, 359-362.	1.7	4
42	Prevalence of pulmonary hypertension in myelofibrosis. <i>Annals of Hematology</i> , 2020, 99, 781-789.	0.8	9
43	Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. <i>Cardiovascular Pathology</i> , 2020, 47, 107211.	0.7	31
44	Differentiation of Cardiac Masses by Cardiac Magnetic Resonance Imaging. <i>Current Cardiovascular Imaging Reports</i> , 2020, 13, 1.	0.4	18
45	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , 2020, 9, e013757.	1.6	240
46	Management strategies and clinical outcomes of acute myocardial infarction in leukaemia patients: Nationwide insights from United States hospitalisations. <i>International Journal of Clinical Practice</i> , 2020, 74, e13476.	0.8	9
47	Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management. <i>International Journal of Cardiology</i> , 2020, 313, 1-8.	0.8	16
48	Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 277-285.	0.8	9
49	Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients. , 2020, , 711-732.		3
50	Acute coronary syndromes in cancer patients. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 944-952.	0.6	5
51	Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 113-120.	0.6	10
52	Interventional Cardiology in the Cancer Patient. , 2020, , 787-806.		0
53	The impact of therapeutic mediastinal radiation on stent healing in cancer patients: An optical coherence tomography study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19096-e19096.	0.8	0
54	Coronary intervention in cancer patients: the need for personalized cardiac care. <i>Revista Romana De Cardiologie</i> , 2020, 30, 389-398.	0.0	0

#	ARTICLE	IF	CITATIONS
55	The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment (Review). <i>Oncology Letters</i> , 2019, 17, 4126-4132.	0.8	4
56	Editorial Commentary: Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 40.	2.3	1
57	The Onco-cardiologist Dilemma: to Implant, to Defer, or to Avoid Transcatheter Aortic Valve Replacement in Cancer Patients with Aortic Stenosis?. <i>Current Cardiology Reports</i> , 2019, 21, 83.	1.3	11
58	Percutaneous Coronary Intervention and Outcomes in Patients With Lymphoma in the United States (Nationwide Inpatient Sample [NIS] Analysis). <i>American Journal of Cardiology</i> , 2019, 124, 1190-1197.	0.7	15
59	Multimodality imaging in carcinoid heart disease. <i>Open Heart</i> , 2019, 6, e001060.	0.9	15
60	Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors. <i>American Journal of Cardiology</i> , 2019, 123, 1351-1357.	0.7	41
61	Applications of Cardiac Computed Tomography in the Cardio-Oncology Population. <i>Current Treatment Options in Oncology</i> , 2019, 20, 47.	1.3	15
62	Interventional Cardiology in the Cancer Patient. , 2019, , 1-20.		0
63	Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients. , 2019, , 1-23.		0
64	Clinical outcomes of percutaneous mitral valve repair with MitraClip for the management of functional mitral regurgitation. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 820-826.	0.7	15
65	Refractory radiation-induced coronary artery disease: mapping the path and guiding treatment with optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 759-760.	0.7	6
66	Carcinoid Heart Disease: a Comprehensive Review. <i>Current Cardiology Reports</i> , 2019, 21, 140.	1.3	11
67	Cardiac Interventional Procedures in Cardio-Oncology Patients. <i>Cardiology Clinics</i> , 2019, 37, 469-486.	0.9	5
68	Skip Soft Definitions and Focus on Hard Endpoints. <i>JACC: CardioOncology</i> , 2019, 1, 218-220.	1.7	0
69	Cardiac toxicities of anticancer treatments. <i>Current Opinion in Cardiology</i> , 2019, 34, 441-450.	0.8	16
70	Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. <i>Cardiovascular Toxicology</i> , 2019, 19, 382-387.	1.1	17
71	Cardiovascular manifestations of Erdheim-Chester disease. <i>Echocardiography</i> , 2019, 36, 229-236.	0.3	24
72	An update on the management and outcomes of cancer patients with severe aortic stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 438-445.	0.7	22

#	ARTICLE	IF	CITATIONS
73	Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. <i>European Heart Journal</i> , 2019, 40, 1790-1800.	1.0	115
74	Expression of T-cell populations and molecular markers of human myocardium with checkpoint-induced myocarditis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 79-79.	0.8	2
75	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. <i>Journal of Cardiovascular Imaging</i> , 2019, 27, 268.	0.2	30
76	Predictors of mortality following cardiac surgery for carcinoid heart disease.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15692-e15692.	0.8	0
77	Impact of pericardial effusion for patients receiving immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14121-e14121.	0.8	1
78	A Cancer Paradox: Machine-Learning Backed Propensity-Score Analysis of Coronary Angiography Findings in Cardio-Oncology. <i>Journal of Invasive Cardiology</i> , 2019, 31, 21-26.	0.4	8
79	Arterial Thrombosis in Patients with Cancer. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 40.	0.4	56
80	Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis. <i>Current Atherosclerosis Reports</i> , 2018, 20, 10.	2.0	31
81	Transcatheter closure of patent foramen ovale for secondary prevention of ischemic stroke: Quantitative synthesis of pooled randomized trial data. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1153-1160.	0.7	13
82	Evaluation and Management of Cardiac Tumors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 29.	0.4	58
83	Simultaneous Congenital Anomaly, Stenosis, and Compression. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2537-2539.	1.1	0
84	Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis. <i>Open Heart</i> , 2018, 5, e000881.	0.9	38
85	Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia. <i>American Journal of Cardiology</i> , 2018, 122, 1465-1470.	0.7	36
86	Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 48.	1.1	13
87	Coronary Lesions in Takayasu Arteritis With Chronic Myelogenous Leukemiaâ€• Intravascular Assessment With Optical Coherence Tomography and Fractional Flow Reserve â€•. <i>Circulation Journal</i> , 2018, 83, 245-246.	0.7	4
88	Acute Coronary Syndrome Management in Cancer Patients. <i>Current Oncology Reports</i> , 2018, 20, 78.	1.8	27
89	Acute Coronary Syndrome in Patients with Cancer. , 2018, , 81-92.		0
90	Chronic thrombocytopenia in cancer patients: Impact on percutaneous coronary intervention and antiplatelet therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22092-e22092.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Clinical outcomes after fractional flow reserve-guided treatment of oncology patients.. Journal of Clinical Oncology, 2018, 36, e22106-e22106.	0.8	1
92	Effect of Pulmonary Hypertension and Other Cardiovascular Diseases in Overall Prognosis of Patients with Myelofibrosis. Blood, 2018, 132, 4310-4310.	0.6	0
93	Impact of cardiopulmonary resuscitation (CPR) on the survival of patients with cancer: DNR before or after cardiac arrest?. Journal of Clinical Oncology, 2018, 36, 71-71.	0.8	4
94	Cancer as a Risk Factor for Cardiovascular Disease. Current Oncology Reports, 2017, 19, 39.	1.8	60
95	Ischemic Heart Disease: Special Considerations in Cardio-Oncology. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 37.	0.4	11
96	Management of CAD in Patients with Active Cancer: the Interventional Cardiologistsâ€™ Perspective. Current Cardiology Reports, 2017, 19, 56.	1.3	18
97	Managing Post-Pneumonectomy Tension Hydrothorax. Annals of the American Thoracic Society, 2017, 14, 1031-1035.	1.5	4
98	Carcinoid heart disease. Heart, 2017, 103, 1488-1495.	1.2	56
99	â€œBringing on the lightâ€•in a complex clinical scenario: Optical coherence tomographyâ€•guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT) Tj ETQq1 1 0.784314 2gBT /Ov	0.7	50
100	Stress-Induced Cardiomyopathy in Cancer Patients. American Journal of Cardiology, 2017, 120, 2284-2288.	0.7	50
101	Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. Canadian Journal of Cardiology, 2017, 33, 1335.e13-1335.e15.	0.8	46
102	The role of cardiac MRI in cardio-oncology. Future Cardiology, 2017, 13, 311-316.	0.5	3
103	Association between ibrutinib and mid-cavitary Takotsubo cardiomyopathy: a case report and a review of chemotherapy-induced Takostuboâ€™s cardiomyopathy. European Heart Journal - Case Reports, 2017, 1, ytx006.	0.3	4
104	Miscellaneous Syndromes (Takotsubo's, Orthostasis, and Differentiation Syndrome). , 2016, , 291-312.		0
105	Resolution of Myelofibrosisâ€™Associated Pulmonary Arterial Hypertension following Allogeneic Hematopoietic Stem Cell Transplantation. Pulmonary Circulation, 2016, 6, 611-613.	0.8	14
106	Vascular Toxicities of Cancer Therapies. Circulation, 2016, 133, 1272-1289.	1.6	270
107	Echocardiography and Fluoroscopy-Guided Pericardiocentesis for Cancer Patients With Cardiac Tamponade and Thrombocytopenia. Journal of the American College of Cardiology, 2016, 68, 771-773.	1.2	14
108	Takotsubo Stress Cardiomyopathy. Journal of the American College of Cardiology, 2016, 68, 1143-1144.	1.2	31

#	ARTICLE	IF	CITATIONS
109	Response by Herrmann et al to Letter Regarding Article, "Vascular Toxicities of Cancer Therapies: The Old and the New" An Evolving Avenue. Circulation, 2016, 134, e466-e467.	1.6	6
110	SCAI expert consensus statement: Evaluation, management, and special considerations of cardiovascular oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Cardiovascular Interventions, 2016, 87, 895-899.	0.7	118
111	<scp>SCAI</scp> Expert consensus statement: Evaluation, management, and special considerations of cardiovascular oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological) Tj ETQq1 1 0.784314 rgBT /Overlock Cardiovascular Interventions, 2016, 87, E202-23.	0.7	152
112	Radiation Toxicity to the Cardiovascular System. Current Oncology Reports, 2016, 18, 15.	1.8	28
113	Cardiovascular Health of Patients With Cancer and Cancer Survivors. Journal of the American College of Cardiology, 2015, 65, 2739-2746.	1.2	198
114	Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion. Journal of the American College of Cardiology, 2015, 66, 1119-1128.	1.2	93
115	Radiation-related heart and vascular disease. Future Oncology, 2015, 11, 2067-2076.	1.1	18
116	Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients. American Journal of Cardiology, 2014, 113, 1893-1898.	0.7	33
117	Cardiovascular interventions in thrombocytopenic cancer patients. Texas Heart Institute Journal, 2011, 38, 259-60.	0.1	30
118	Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. Texas Heart Institute Journal, 2010, 37, 336-40.	0.1	36